200 related articles for article (PubMed ID: 14559903)
1. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library.
Shiraishi K; Kato S; Han SY; Liu W; Otsuka K; Sakayori M; Ishida T; Takeda M; Kanamaru R; Ohuchi N; Ishioka C
J Biol Chem; 2004 Jan; 279(1):348-55. PubMed ID: 14559903
[TBL] [Abstract][Full Text] [Related]
2. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
3. Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations.
Koulgi S; Achalere A; Sonavane U; Joshi R
PLoS One; 2015; 10(11):e0143065. PubMed ID: 26579714
[TBL] [Abstract][Full Text] [Related]
4. Isolation of Fission Yeast Condensin Temperature-Sensitive Mutants with Single Amino Acid Substitutions Targeted to Hinge Domain.
Xu X; Yanagida M
G3 (Bethesda); 2019 May; 9(5):1777-1783. PubMed ID: 30914423
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the p53 core domain L1 loop.
Zupnick A; Prives C
J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
[TBL] [Abstract][Full Text] [Related]
6. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
7. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
8. Specific DNA binding by different classes of human p53 mutants.
Rolley N; Butcher S; Milner J
Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
[TBL] [Abstract][Full Text] [Related]
9. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
10. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
Joerger AC; Allen MD; Fersht AR
J Biol Chem; 2004 Jan; 279(2):1291-6. PubMed ID: 14534297
[TBL] [Abstract][Full Text] [Related]
12. A genetic approach to mapping the p53 binding site in the MDM2 protein.
Freedman DA; Epstein CB; Roth JC; Levine AJ
Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
[TBL] [Abstract][Full Text] [Related]
13. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
15. Common conformational effects of p53 mutations.
Chen JM; Rosal R; Smith S; Pincus MR; Brandt-Rauf PW
J Protein Chem; 2001 Feb; 20(2):101-5. PubMed ID: 11563689
[TBL] [Abstract][Full Text] [Related]
16. Structural correlates of the temperature sensitive phenotype derived from saturation mutagenesis studies of CcdB.
Bajaj K; Dewan PC; Chakrabarti P; Goswami D; Barua B; Baliga C; Varadarajan R
Biochemistry; 2008 Dec; 47(49):12964-73. PubMed ID: 19006334
[TBL] [Abstract][Full Text] [Related]
17. Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.
Kovvali GK; Mehta B; Epstein CB; Lutzker SG
Nucleic Acids Res; 2001 Mar; 29(5):E28. PubMed ID: 11222779
[TBL] [Abstract][Full Text] [Related]
18. A split-ubiquitin-based assay detects the influence of mutations on the conformational stability of the p53 DNA binding domain in vivo.
Johnsson N
FEBS Lett; 2002 Nov; 531(2):259-64. PubMed ID: 12417323
[TBL] [Abstract][Full Text] [Related]
19. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
[TBL] [Abstract][Full Text] [Related]
20. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
